Alcon acquires Optonol

Article

Alcon acquires Optinol and enters glaucoma surgical market.

Alcon has entered into the surgical glaucoma market by acquiring Optonol, a manufacturer and marketer of novel minature surgical implants used to reduce IOP.

The move will enable Alcon to acquire the Ex-PRESS Mini Glaucoma Shunt to complement its pharmaceutical products that lower IOP. “The acquisition of Optonol is part of our strategy to bolster organic growth with targeted investments in key therapeutic areas that have the potential to contribute in both the near and long term,” said Kevin Buehler, Alcon's president and chief executive officer. “Because the product is already approved in the United States and other major markets it will begin contributing commercially in 2010.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.